AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Jun 2021 07:00 AM
RNS
Lynparza approved in China for prostate cancer
23 Jun 2021 07:00 AM
RNS
Orpathys approved in China for lung cancer
22 Jun 2021 07:00 AM
RNS
Koselugo approved in the EU for children with NF1
15 Jun 2021 07:00 AM
RNS
Update on AZD7442 STORM CHASER trial
07 Jun 2021 07:00 AM
RNS
Calquence head-to-head results versus ibrutinib
04 Jun 2021 07:05 AM
RNS
Lynparza reduced recurrence risk in breast cancer
04 Jun 2021 07:00 AM
RNS
AstraZeneca appoints new Chief Financial Officer
02 Jun 2021 07:00 AM
RNS
Publication of Final Terms
01 Jun 2021 03:01 PM
RNS
Block listing Interim Review
01 Jun 2021 03:00 PM
RNS
Total Voting Rights
28 May 2021 07:00 AM
RNS
Tagrisso approved in EU in early lung cancer
27 May 2021 04:41 PM
RNS
Second Price Monitoring Extn
27 May 2021 04:36 PM
RNS
Price Monitoring Extension
27 May 2021 07:00 AM
RNS
AstraZeneca prices a EUR800m bond offering
26 May 2021 07:00 AM
RNS
AstraZeneca prices a $7bn bond offering
25 May 2021 07:00 AM
RNS
EMTN programme update - publication of Prospectus
21 May 2021 07:00 AM
RNS
Vaxzevria COVID-19 vaccine approved in Japan
18 May 2021 03:30 PM
RNS
Director/PDMR Shareholding
11 May 2021 02:00 PM
RNS
Result of AGM
11 May 2021 01:55 PM
RNS
Shareholders vote in favour of Alexion acquisition
07 May 2021 07:00 AM
RNS
Imfinzi + tremelimumab showed survival in POSEIDON
04 May 2021 03:00 PM
RNS
Total Voting Rights
04 May 2021 07:00 AM
RNS
Farxiga approved in the US for CKD
30 Apr 2021 07:00 AM
RNS
AZN: First quarter 2021 results
26 Apr 2021 07:10 AM
RNS
Selumetinib recommended for EU approval in NF1
26 Apr 2021 07:05 AM
RNS
Tagrisso adjuvant receives positive CHMP opinion
26 Apr 2021 07:00 AM
RNS
Nirsevimab Phase III trial met primary endpoint
16 Apr 2021 12:00 PM
RNS
US clearance of proposed acquisition of Alexion
14 Apr 2021 07:00 AM
RNS
Tagrisso approved in China in early lung cancer
12 Apr 2021 01:00 PM
RNS
Circular and notice of general meeting
12 Apr 2021 07:00 AM
RNS
Update on Farxiga COVID-19 DARE-19 Phase III trial
01 Apr 2021 03:00 PM
RNS
Total Voting Rights
30 Mar 2021 12:15 PM
RNS
Notice of AGM
25 Mar 2021 03:00 PM
RNS
Director/PDMR Shareholding
25 Mar 2021 07:00 AM
RNS
AZD1222 US Ph3 primary analysis confirms efficacy
22 Mar 2021 07:00 AM
RNS
AstraZeneca US vaccine trial met primary endpoint
16 Mar 2021 07:05 AM
RNS
Divestment of Viela shareholding completed
16 Mar 2021 07:00 AM
RNS
US supply agreement for additional AZD7442 doses
09 Mar 2021 03:00 PM
RNS
Director/PDMR Shareholding
04 Mar 2021 03:00 PM
RNS
Designation of EU home member state
03 Mar 2021 07:00 AM
RNS
US court decision favours Symbicort patents
02 Mar 2021 07:00 AM
RNS
Further update on roxadustat US regulatory review
01 Mar 2021 03:00 PM
RNS
Total Voting Rights
22 Feb 2021 07:00 AM
RNS
Voluntary withdrawal Imfinzi US bladder indication
17 Feb 2021 07:00 AM
RNS
Lynparza: IDMC recommend early analysis of OlympiA
16 Feb 2021 11:15 AM
RNS
Filing of Form 20-F with SEC
15 Feb 2021 03:00 PM
RNS
Director/PDMR Shareholding
15 Feb 2021 11:00 AM
RNS
Annual Financial Report
11 Feb 2021 07:01 AM
RNS
AstraZeneca Non-Executive Board changes
11 Feb 2021 07:00 AM
RNS
AZN: full-year 2020 results
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100